This site requires JavaScript and cookies to be enabled.

Once-daily dosing with Qelbree

Several million prescriptions have been written for Qelbree, a nonstimulant that offers a convenient, once-daily dosing schedule (either AM or PM) for
24-hour exposure.1,2*

*Source: IQVIA NPA data, as of March 31, 2026.

Qelbree provides
24-hour exposure in a single daily dose1,2

Qelbree provides a rapid- and extended-release platform for children, teens, and adults with ADHD.2

Qelbree mechanism of delivery

Qelbree offers 3 dosage strengths for flexibility1

 

Qelbree is available in 3 capsule strengths1:

Qelbree 100 mg yellow capsule imprinted with "SPN 100"
Qelbree 150 mg light blue capsule imprinted with "SPN 150"
200 mg capsule

Capsules shown are not actual size.

Titrate Qelbree weekly as needed to optimize ADHD symptom control1

Titrate depending on response and tolerability.

 

 

Children: Start at 100 mg/day and titrate Qelbree weekly as needed to optimize ADHD symptom control1

A titration schedule for children (6-11 years) outlines a starting dose of Qelbree at 100 mg/day for Week 1, which can be titrated upward weekly in 100 mg increments over 1 to 3 weeks (200 mg/day in Week 2, 300 mg/day in Week 3, and 400 mg/day in Week 4) as needed to reach an effective dose, up to a maximum dose of 400 mg/day.

 

 

Teens: Start at 200 mg/day and titrate Qelbree weekly as needed to optimize ADHD symptom control1

A titration schedule for teens (12-17 years) outlines a starting dose of Qelbree at 200 mg/day for Week 1, which can be titrated upward over 1 week to 400 mg/day in Week 2 as needed to reach an effective dose, up to a maximum dose of 400 mg/day.

 

 

Adults: Start at 200 mg/day and titrate Qelbree weekly as needed to optimize ADHD symptom control1

A titration schedule for adults (18-65 years) outlines a starting dose of Qelbree at 200 mg/day for Week 1, which can be titrated upward weekly in 200 mg increments over 1 to 2 weeks (400 mg/day in Week 2 and 600 mg/day in Week 3) as needed to reach an effective dose, up to a maximum dose of 600 mg/day.

Adult Phase III (Study P306) mean dose at EOS (6 weeks) was 504 mg/day

  • Severe renal impairment: Initiate Qelbree at 100 mg and increase by 50 mg to 100 mg at weekly intervals to a maximum recommended dosage of 200 mg once daily
Icon Dosing

Download the Qelbree dosing guide

This easy-to-use guide outlines key dosing information for children, teens, and adults with ADHD.

Qelbree Dosing Guide
Qelbree Dosing Guide

 

Qelbree offers flexibility to fit ADHD patients’ needs1

Qelbree can be taken 2 ways:

Capsule can be taken whole or entire contents can be sprinkled over a spoonful of soft food (pudding or applesauce). Consume the mixture in its entirety, without chewing, within 15 minutes for pudding or within 2 hours for applesauce; do not store for future use.1

  • Capsules and their contents should not be cut, crushed, or chewed1
  • Can be taken with or without food1
You can take Qelbree in two ways: swallowing the capsule whole with a glass of water or opening the capsule and sprinkling the beads onto a spoonful of applesauce or pudding.

Dosing can align with their schedule—prescribe once-daily (either AM or PM) for 24-hour exposure1,2

You can take Qelbree at either daytime or nighttime.

Qelbree is a nonstimulant ADHD treatment with no evidence of abuse potential1,3,4

Once-daily Qelbree shows no evidence of abuse potential—minimizing risk of treatment abuse, misuse, or diversion.1,3,4

Qelbree mechanism of delivery

A young woman working at her laptop
A young woman working at her laptop

Qelbree can be conveniently refilled without a new prescription each month

Qelbree is a nonstimulant therapy.1 You may be able to prescribe a 90-day supply for more convenience.

Abbreviation: ADHD, attention-deficit/hyperactivity disorder.

 

Discover more:

Savings Card  Access and support  Request samples 

I love that it’s a nonstimulant. It’s not a controlled substance. You don’t have to call the office every month to get a refill for your prescription, and you can get a 90-day supply in most cases.

– Jo Hughes, PA-C, CAQ-PSY, DMSc

Watch their video

Stay informed

Get Qelbree email updates, savings information, and links to helpful resources for you and your patients.

Sign up 

IMPORTANT SAFETY INFORMATION

INDICATION

Qelbree (viloxazine extended-release capsules) is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in [read more] patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all [read more] Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

CONTRAINDICATIONS

  • Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
  • Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

  • Suicidal thoughts and behaviors: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
  • Heart rate, blood pressure increases: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
  • Activation of mania or hypomania: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression 
  • Somnolence and fatigue: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree 

ADVERSE REACTIONS

The most common adverse reactions (≥ 5% and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation. 

PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting www.womensmentalhealth.org/preg. 

Please see full Prescribing Information, including Boxed Warning.

References:

1. Qelbree [package insert]. Rockville, MD: Supernus Pharmaceuticals, Inc.
2. Data on file, Supernus Pharmaceuticals, Inc.
3. Key prescription stimulant label updates. U.S. Food and Drug Administration. May 11, 2023. Accessed May 15, 2026. https://www.fda.gov/media/168050/download
4. Yanagita T, Wakasa Y, Kiyohara H. Drug dependence potential of viloxazine hydrochloride tested in rhesus monkeys. Pharmacol Biochem Behav. 1980;12(1):155-161. doi:10.1016/0091-3057(80)90430-x 1

IMPORTANT SAFETY INFORMATION

INDICATION

Qelbree (viloxazine extended-release capsules) is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in [read more] patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all [read more] Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

CONTRAINDICATIONS

  • Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
  • Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

  • Suicidal thoughts and behaviors: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
  • Heart rate, blood pressure increases: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
  • Activation of mania or hypomania: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression 
  • Somnolence and fatigue: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree 

ADVERSE REACTIONS

The most common adverse reactions (≥ 5% and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation. 

PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting www.womensmentalhealth.org/preg. 

Please see full Prescribing Information, including Boxed Warning.